5-Methoxy-N-propyl-N-isopropyltryptamine (5-MeO-PiPT) is a substituted tryptamine derivative which is claimed to have psychedelic effects. It acts as a 5-HT1A and 5-HT2A receptor agonist,[1] with an EC50 of 13.8 nM and an efficacy of 89% (vs 5-HT),[2] and has been sold as a designer drug, first being identified in 2021 in British Columbia, Canada.[3]

5-MeO-PiPT
Identifiers
  • N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-(propan-2-yl)propan-1-amine
PubChem CID
Chemical and physical data
FormulaC17H26N2O
Molar mass274.408 g·mol−1
3D model (JSmol)
  • CC(C)N(CCC)CCc1c[NH]c2ccc(cc21)OC
  • InChI=1S/C17H26N2O/c1-5-9-19(13(2)3)10-8-14-12-18-17-7-6-15(20-4)11-16(14)17/h6-7,11-13,18H,5,8-10H2,1-4H3
  • Key:KLRSMSBDLVDLKK-UHFFFAOYSA-N

See also

edit

References

edit
  1. ^ Warren AL, Lankri D, Cunningham MJ, Serrano IC, Parise LF, Kruegel AC, Duggan P, Zilberg G, Capper MJ, Havel V, Russo SJ, Sames D, Wacker D. Structural pharmacology and therapeutic potential of 5-methoxytryptamines. Nature. 2024 Jun;630(8015):237-246. doi:10.1038/s41586-024-07403-2 PMID 38720072
  2. ^ Banister S, Jorgensen W, Jinlong T. Compounds. Patent WO 2023/115167
  3. ^ Knill A, Tobias S, Matthews J, Ti L (June 2022). A Report on British Columbia's Unregulated Drug Supply. Drug checking trends across British Columbia, January to December 2021 (PDF). British Columbia Centre on Substance Use (Report).